Are you Dr. Dennis?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 95 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4940 Eastern Ave
Johns Hopkins Bayview Medical Center
Baltimore, MD 21224Phone+1 410-550-9250Fax+1 410-550-5445
Summary
- Dr. Phillip Dennis, MD is an oncologist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1995 - 1998- Johns Hopkins UniversityResidency, Internal Medicine, 1992 - 1995
New York University School of MedicineClass of 1992
Certifications & Licensure
MD State Medical License 1995 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Elected Member The American Society for Clinical Investigation, 2007
Clinical Trials
- Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Start of enrollment: 2012 May 01
- Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- 2 citationsInhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.Yoon Soo Chang, Joell J Gills, Shigeru Kawabata, Masahiro Onozawa, Giusy Della Gatta
International Journal of Oncology. 2023-11-01 - 23 citationsResistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3...Nabendu Pore, Song Wu, Nathan Standifer, Maria Jure-Kunkel, Melissa de los Reyes
Cancer Discovery. 2021-07-06 - 25 citationsDurvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).Mark A. Socinski, Mustafa Ozguroglu, A. Villegas, Davey B. Daniel, David Vicente
Clinical Lung Cancer. 2021-06-12
Press Mentions
Post-Trial NSCLC Immunotherapy: Do Positive Vibes Linger On?September 13th, 2019
